Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

References

• ChenWZhengRZengHZhangSThe incidence and mortality of major cancers in China, 2012Chin J Cancer20163517327484217
   PubMedGoogle Scholar
• HongQYWuGMQianGSPrevention and management of lung cancer in ChinaCancer2015121Suppl 173080308826331814
   PubMed Web of Science ®Google Scholar
• LiQHsiaJYangGPrevalence of smoking in China in 2010N Engl J Med2011364252469247021696322
   PubMed Web of Science ®Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• YangLParkinDMFerlayJLiLChenYEstimates of cancer incidence in China for 2000 and projections for 2005Cancer Epidemiol Biomarkers Prev200514124325015668501
   PubMed Web of Science ®Google Scholar
• YouldenDRCrambSMBaadePDThe International Epidemiology of Lung Cancer: geographical distribution and secular trendsJ Thorac Oncol20083881983118670299
   PubMed Web of Science ®Google Scholar
• ZhangHCaiBThe impact of tobacco on lung health in ChinaRespirology200381172112856737
   PubMed Web of Science ®Google Scholar
• ChenWZhengRZengHZhangSEpidemiology of lung cancer in ChinaThorac Cancer20156220921526273360
   PubMed Web of Science ®Google Scholar
• GaoYZhangJFLiQCThe clinicopathological and prognostic features of Chinese and Japanese inpatients with lung cancerOncotarget2016741674256743427608841
   PubMedGoogle Scholar
• ZhouQWuYLDeveloping CSCO lung cancer practice guidelines stratified by resource availability and treatment valueJ Glob Oncol20163428528828831436
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMBunnPAJrEpidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol200321203798380712953099
   PubMed Web of Science ®Google Scholar
• ZugazagoitiaJPonceSPaz-AresLNecitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?Transl Lung Cancer Res201651959726958500
   PubMed Web of Science ®Google Scholar
• HirshVNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinibOnco Targets Ther2017102513252628546756
   PubMed Web of Science ®Google Scholar
• SoriaJCFelipECoboMAfatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialLancet Oncol201516889790726156651
   PubMed Web of Science ®Google Scholar
• FelipEHirshVPopatSSymptom and quality of life improvement in LUX-Lung 8, an open-label Phase III study of second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapyClin Lung Cancer201819174.e1183.e1128729180
   PubMed Web of Science ®Google Scholar
• TanakaKAkechiTOkuyamaTNishiwakiYUchitomiYImpact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancerJ Pain Symptom Manage200223541742312007759
   PubMed Web of Science ®Google Scholar
• AaronsonNKAhmedzaiSBergmanBThe European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst19938553653768433390
   PubMed Web of Science ®Google Scholar
• BergmanBAaronsonNKAhmedzaiSKaasaSSullivanMThe EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of LifeEur J Cancer199430A56356428080679
   PubMed Web of Science ®Google Scholar
• European Organisation for Research and Treatment of CancerThe EORTC QLQ-C30 scoring manualEuropean Organisation for Research and Treatment of Cancer2001 Available from: http://www.eortc.be/qol/files/SCManualQLQ-c30.pdfAccessed June 4, 2018
   Google Scholar
• GadgeelSMSoriaJCFelipESecond-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term respondersEur J Cancer2017721S185
   Web of Science ®Google Scholar
• MeropolNJEglestonBLBuzagloJSCancer patient preferences for quality and length of lifeCancer2008113123459346618988231
   PubMed Web of Science ®Google Scholar
• YangJCReguartNBarinoffJDiarrhea associated with afatinib: an oral ErbB family blockerExpert Rev Anticancer Ther201313672973623506556
   PubMed Web of Science ®Google Scholar
• DeardenSStevensJWuYLBlowersDMutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Ann Oncol20132492371237623723294
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbHGilotrif US Prescribing Information2016 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdfGiotrifAccessed February 13, 2017
   Google Scholar
• GIOTRIF^® (afatinib) tablets, for oral use [prescribing information]Boehringer Ingelheim International GmbH2016
   Google Scholar
• YangJCSequistLVZhouCEffect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsAnn Oncol201627112103211027601237
   PubMed Web of Science ®Google Scholar